JPRN-UMIN000012030招募中2 期
A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancer - A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancer
Saitama Breast Cancer Clinical Study Group0 个研究点目标入组 30 人开始时间: 2013年10月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1.Patients received capecitabine,pertuzumab. 2.Have hypersensitivity to Trastuzumab. 3.History of allergic reactions for capecitabine or fluoropyrimidines. 4.Patient during the therapy enforcement of immunity or hormon therapy. 5..During pregnancy or lactation. 6.Symptomatic brain metastasis. 7.With uncontrollable hypertension, angina, congestive heart failure, myocardial infection within 1 year, arrhythmia, valvular heart disease. 8.Pulmonary fibrosis or pneumonia. 9.Dyspnea at rest. 10.With pleural effusion, ascites, pericardial effusion. 11Active infection or potentiality infection. 12.Serious drug allergy. 13.Active double cancer. 14.Only bone metastasis. 15.Judged by the investigator to be unfit to be enrolled into the study.
研究者
相似试验
已完成
2 期
A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.Breast cancerJPRN-UMIN000012208Kurume University Hospital24
已完成
2 期
Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab TherapyHER2-Positive Metastatic Breast CancerJPRN-UMIN000012452Chiba Youth Breast Oncology Research Group (CYBORG)35
暂停
不适用
Phase II trial of pertuzumab and trastuzumab in combination with S-1 for patients with HER2-positive metastatic breast cancerBreast cancerJPRN-UMIN000024477Kurume University School of Medicine32
进行中（未招募）
2 期
Extension study for HER2 amplified advanced solid tumors (JUPITER ES)JPRN-jRCTs031220444Ikeda Sadakatsu3
已完成
不适用
Early monitoring of trastuzumab +/- pertuzumab therapy with 18F-choline PET/CT in patients with advanced disease breastcancer.NL-OMON39351Catharina-ziekenhuis23